BRPI0414442A - composições de vacina de dna e métodos de utilização - Google Patents

composições de vacina de dna e métodos de utilização

Info

Publication number
BRPI0414442A
BRPI0414442A BRPI0414442-2A BRPI0414442A BRPI0414442A BR PI0414442 A BRPI0414442 A BR PI0414442A BR PI0414442 A BRPI0414442 A BR PI0414442A BR PI0414442 A BRPI0414442 A BR PI0414442A
Authority
BR
Brazil
Prior art keywords
methods
dna vaccine
dna molecule
vaccine compositions
dna
Prior art date
Application number
BRPI0414442-2A
Other languages
English (en)
Inventor
Opendra Narayan
Zhenqian Liu
Original Assignee
Univ Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas Medical Center filed Critical Univ Kansas Medical Center
Publication of BRPI0414442A publication Critical patent/BRPI0414442A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçõES DE VACINA DE DNA E MéTODOS DE UTILIZAçãO". A presente invenção refere-se a uma vacina de DNA para imunização contra o HIV. A presente invenção compreende uma molécula de DNA que possui uma seqüência codificando diversas proteínas virais capazes de estimular uma resposta imunológica contra o HIV. A molécula de DNA é apresentada como sendo segura para utilização na forma de uma vacina devido à ruptura dos genes que codificam a transcritase reversa, a integrase e a Vif. A molécula de DNA é adicionalmente apresentada como segura devido, pelo menos, a uma eliminação parcial da LTR 3<39>.
BRPI0414442-2A 2003-09-16 2004-09-16 composições de vacina de dna e métodos de utilização BRPI0414442A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50319703P 2003-09-16 2003-09-16
US10/941,164 US7488485B2 (en) 2003-09-16 2004-09-15 DNA vaccine compositions and methods of use
PCT/US2004/030512 WO2005027844A2 (en) 2003-09-16 2004-09-16 Dna vaccine compositions and methods of use

Publications (1)

Publication Number Publication Date
BRPI0414442A true BRPI0414442A (pt) 2006-11-14

Family

ID=34381064

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414442-2A BRPI0414442A (pt) 2003-09-16 2004-09-16 composições de vacina de dna e métodos de utilização

Country Status (13)

Country Link
US (3) US7488485B2 (pt)
EP (1) EP1667523B1 (pt)
JP (1) JP4989224B2 (pt)
AU (1) AU2004273965B2 (pt)
BR (1) BRPI0414442A (pt)
CA (1) CA2538840C (pt)
DK (1) DK1667523T3 (pt)
ES (1) ES2399875T3 (pt)
IL (1) IL174325A (pt)
NZ (1) NZ545954A (pt)
PL (1) PL1667523T3 (pt)
PT (1) PT1667523E (pt)
WO (1) WO2005027844A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488485B2 (en) * 2003-09-16 2009-02-10 University Of Kansas Medical Center DNA vaccine compositions and methods of use
US8785411B2 (en) * 2003-09-16 2014-07-22 University Of Kansas Medical Center HIV DNA vaccine methods of use
EP2913403A1 (en) * 2005-05-03 2015-09-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Importation of mitochondrial protein by an enhanced allotopic approach
US7585675B2 (en) * 2005-11-15 2009-09-08 University Of Kansas Medical Center Inhibition of HIV and SHIV replication with antisense interleukin-4
FR2979919B1 (fr) 2011-09-12 2015-12-11 Centre Nat Rech Scient Genomes lentiviraux chimeriques non-integratifs comme vaccins innovants contre vih-1
WO2013126469A1 (en) * 2012-02-21 2013-08-29 Immunogenetix Therapeutics, Inc. Chimeric dna vaccine compositions and methods of use
KR102922000B1 (ko) 2019-07-16 2026-02-05 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
JP7693813B2 (ja) 2021-01-14 2025-06-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン及び使用方法
WO2022152939A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6531123B1 (en) * 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
US7488485B2 (en) * 2003-09-16 2009-02-10 University Of Kansas Medical Center DNA vaccine compositions and methods of use
US7122180B2 (en) * 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses

Also Published As

Publication number Publication date
US20120207782A1 (en) 2012-08-16
WO2005027844A2 (en) 2005-03-31
CA2538840A1 (en) 2005-03-31
EP1667523A2 (en) 2006-06-14
CA2538840C (en) 2014-02-18
IL174325A0 (en) 2008-04-13
AU2004273965A1 (en) 2005-03-31
JP2007505923A (ja) 2007-03-15
IL174325A (en) 2015-07-30
JP4989224B2 (ja) 2012-08-01
EP1667523B1 (en) 2012-11-21
NZ545954A (en) 2009-04-30
DK1667523T3 (da) 2013-01-21
ES2399875T3 (es) 2013-04-04
PT1667523E (pt) 2013-02-04
PL1667523T3 (pl) 2013-05-31
WO2005027844A3 (en) 2005-10-06
US20090233857A1 (en) 2009-09-17
US8916174B2 (en) 2014-12-23
US20050112102A1 (en) 2005-05-26
EP1667523A4 (en) 2007-12-19
US7488485B2 (en) 2009-02-10
US8003113B2 (en) 2011-08-23
AU2004273965B2 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
CY1109667T1 (el) Εμβολιο για προληψη και θεραπεια της λοιμωξης - hiv
PT1404347E (pt) Nucleosidos 4&#39;-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
EA200802209A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
UY27843A1 (es) Composicion de vacuna
JP2009539965A5 (pt)
UY28084A1 (es) Derivados antivirales de nucleosidos
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
ECSP055801A (es) Compuestos benzofuránicos, composiciones y métodos para el tratamiento y profilaxis de infecciones virales de hepatitis c y enfermedades asociadas
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
NO20061912L (no) Vaksinesammensetninger omfattende et interleukin 18 og saponin adjuvant system
NO20061911L (no) Immunogene sammensetninger
DE60142683D1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
BRPI0414442A (pt) composições de vacina de dna e métodos de utilização
BR112022011445A2 (pt) Composição imunoestimuladora e uso da mesma
DE60330708D1 (de) Impfstoff gegen das west-nile-virus
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
BR112015017966A2 (pt) composições imunogênicas compreendendo vírus silificado e métodos de uso
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
BR112015007879A2 (pt) inibidores do vírus da hepatite c
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
BR0317544A (pt) Uso de uma composição que compreende vlps de hpv 16 e hpv 18, e, métodos para induzir uma resposta imune contra um ou mais do grupo de tipos de hpv oncogênicos, para prevenir infecção e/ou doença causada por um ou mais do grupo de tipos de hpv oncogênicos, para prevenir a infecção de uma população de pacientes por um ou mais tipos de hpv, uso de uma mistura de vlps de hpv 16 e hpv18, e, composição de vacina
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
RU2016151973A (ru) Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. CL. A01N 43/04, A01N 63/00, A61K 39/21, C07H 21/04, C12N 15/00, C12N 15/63, C12N 15/86.

Ipc: A61K 39/21 (2006.01), A61K 48/00 (2006.01), C07H 2

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2479 DE 10-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI